Revolution Medicines' oral KRAS inhibitor daraxonrasib (Rasonque), FDA-approved in August 2026, showed tumor shrinkage or disappearance in 60.7% of 61 metastatic pancreatic cancer patients when combined with gemcitabine and nab-paclitaxel. Median progression-free survival reached 12.8 months versus 5-6 months on standard chemotherapy. Results were presented November 21, 2026 in Barcelona, though experts note the trial lacked a randomised control group.
Daraxonrasib trial results
- ▪In the daraxonrasib trial, 76.6 per cent of patients were still alive 12 months after beginning treatment
- ▪In the daraxonrasib trial, 8.2 per cent of patients showed no detectable signs of cancer on scans
- ▪The daraxonrasib trial findings were presented
- ▪Patients in the daraxonrasib trial received a daily 200mg tablet alongside chemotherapy drugs gemcitabine and nab-paclitaxel
- ▪Daraxonrasib combined with chemotherapy produced tumour shrinkage or disappearance in 60.7 per cent of 61 patients with metastatic pancreatic cancer in a clinical trial
- ▪The daraxonrasib trial found that 90.2 per cent of patients had disease progression stopped
- ▪The median time before cancer worsened or patients died in the 61-patient daraxonrasib trial was 12.8 months
Pancreatic cancer treatment context
- ▪In metastatic pancreatic cancer patients on conventional chemotherapy, disease typically begins progressing again after five to six months
- ▪RAS protein mutations are found in more than 90 per cent of pancreatic cancers, causing cells to multiply uncontrollably
- ▪Patients with metastatic pancreatic cancer receiving conventional chemotherapy typically survive for eight to 11 months
- ▪Tumour shrinkage occurs in approximately 23 to 42 per cent of metastatic pancreatic cancer patients receiving conventional chemotherapy
Expert caution on findings
- ▪Five per cent of patients in the 61-patient daraxonrasib trial discontinued treatment because of side effects attributed to daraxonrasib
- ▪Professor Shivan Sivakumar, professor of translational oncology at the University of Birmingham, warned that the daraxonrasib trial involved only 61 patients and lacked a randomised control group
- ▪Researchers cautioned that comparisons of the 61-patient daraxonrasib trial results with historical chemotherapy results cannot establish whether the daraxonrasib combination improves survival
- ▪Some patients in the daraxonrasib trial experienced rashes, diarrhoea, and fatigue
FDA approval status
- ▪Daraxonrasib was developed by US biotechnology company Revolution Medicines
- ▪In the trial supporting FDA approval of daraxonrasib, median overall survival was 13.2 months among patients receiving daraxonrasib, compared with 6.7 months for patients receiving standard chemotherapy
- ▪The FDA approval of daraxonrasib followed a separate trial involving 500 patients
- ▪The US Food and Drug Administration approved daraxonrasib, marketed as Rasonque, in August 2026 for certain patients with metastatic pancreatic cancer who had previously undergone treatment or were unsuitable for combination chemotherapy
Phase III trial outlook
- ▪A larger international Phase III trial called RASolute-303 is investigating whether daraxonrasib, either alone or combined with chemotherapy, can improve outcomes compared with standard chemotherapy
- ▪The RASolute-303 Phase III trial is testing daraxonrasib alone or combined with chemotherapy for metastatic pancreatic cancer, a use that still requires further clinical validation
Story comments
Loading comments…